Letters Rosiglitazone and pioglitazone

Beware fractures

BMJ 2009; 339 doi: http://dx.doi.org/10.1136/bmj.b3957 (Published 29 September 2009) Cite this as: BMJ 2009;339:b3957
  1. Alok Dixit, assistant professor1,
  2. Pinki Pandey, assistant professor1
  1. 1M M Institute of Medical Science and Research, Mullana, Ambala, India 133203
  1. alkdxt{at}yahoo.co.in

    Juurlink and colleagues show that pioglitazone has fewer adverse cardiovascular outcomes than rosiglitazone, which may be a class effect.1 However, recent reports show that thiazolidinediones are associated with increased incidence of …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial